Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(8):582-583; doi:10.1093/jnci/djk147
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Martínez, M. E.
Right arrow Articles by Greenberg, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martínez, M. E.
Right arrow Articles by Greenberg, E. R.
Related Collections
Right arrowEditorial about this Article
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

EDITORIALS

More Aspirin for Less Cancer?

María Elena Martínez, E. Robert Greenberg

Affiliations of authors: Arizona Cancer Center (MEM, ERG), Mel and Enid Zuckerman Arizona College of Public Health (MEM), and Department of Nutrition, College of Agriculture and Life Sciences (MEM), University of Arizona, Tucson, AZ; Department of Community and Family Medicine, Dartmouth Medical School, Hanover, NH (ERG); Fred Hutchinson Cancer Research Center, Seattle, WA (ERG)

Correspondence to: María Elena Martínez, MPH, PhD, Arizona Cancer Center, University of Arizona, PO Box 245024, Tucson, AZ (e-mail: emartinez@azcc.arizona.edu).

The first 10% of the full text of this article appears below.

More than a century after aspirin was first synthesized, its benefits continue to be discovered and now include everything from relief of headaches to cardiovascular disease prevention. Evidence pointing to an association between aspirin and reduced cancer risk is largely derived from epidemiologic studies, although laboratory experiments and a few clinical trials have provided support for this idea. The apparent anticancer effect of aspirin has been seen most consistently for gastrointestinal tract cancers and especially for colorectal cancer (1); it is thought to occur through the drug's ability to inhibit cyclooxygenase enzymes, which are produced by the body when there is inflammation, although alternate hypotheses have been suggested (2).

Prior epidemiologic studies of aspirin and cancer prevention . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Editorial about this Article

A Large Cohort Study of Long-Term Daily Use of Adult-Strength Aspirin and Cancer Incidence
Eric J. Jacobs, Michael J. Thun, Elizabeth B. Bain, Carmen Rodriguez, S. Jane Henley, and Eugenia E. Calle
J Natl Cancer Inst 2007 99: 608-615. [Abstract] [Full Text] [PDF]

Related Articles in JNCI

IN THIS ISSUE
J Natl Cancer Inst 2007 99: 577. [Extract] [Full Text] [PDF]

Press Release: Long-term Use of Adult-Strength Aspirin Linked to a Moderate Decreased Cancer Risk
Liz Savage
J Natl Cancer Inst 2007 99: 577. [Extract] [Full Text]